Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BLRX logo BLRX
Upturn stock ratingUpturn stock rating
BLRX logo

BioLineRx Ltd (BLRX)

Upturn stock ratingUpturn stock rating
$4.57
Last Close (24-hour delay)
Profit since last BUY25.9%
upturn advisory
Regular Buy
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: BLRX (3-star) is a REGULAR-BUY. BUY since 20 days. Profits (25.90%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

2 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $26

Year Target Price $26

Analyst’s Price TargetsFor last 52 week
$26Target price
Low$2.3
Current$4.57
high$35.6

Analysis of Past Performance

Type Stock
Historic Profit 52.27%
Avg. Invested days 25
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 16.48M USD
Price to earnings Ratio -
1Y Target Price 26
Price to earnings Ratio -
1Y Target Price 26
Volume (30-day avg) -
Beta 0.9
52 Weeks Range 2.30 - 35.60
Updated Date 06/29/2025
52 Weeks Range 2.30 - 35.60
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -6

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.21%
Operating Margin (TTM) -937.65%

Management Effectiveness

Return on Assets (TTM) -21.98%
Return on Equity (TTM) -20.03%

Valuation

Trailing PE -
Forward PE 109.89
Enterprise Value 3810269
Price to Sales(TTM) 0.74
Enterprise Value 3810269
Price to Sales(TTM) 0.74
Enterprise Value to Revenue 0.17
Enterprise Value to EBITDA 0.45
Shares Outstanding 3721000
Shares Floating 2139457835
Shares Outstanding 3721000
Shares Floating 2139457835
Percent Insiders 4.08
Percent Institutions 0.22

Analyst Ratings

Rating 4.5
Target Price 26
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

BioLineRx Ltd

stock logo

Company Overview

overview logo History and Background

BioLineRx Ltd. is a biopharmaceutical company focused on oncology. Founded in 2003, it initially in-licensed and developed clinical-stage therapeutic candidates, and later focused on developing its own assets. A key milestone was the FDA approval of Aphexda (motixafortide) in 2023.

business area logo Core Business Areas

  • Oncology: Developing and commercializing therapies for hematological cancers and solid tumors. Core focus is on Aphexda (motixafortide), a CXCR4 inhibitor.

leadership logo Leadership and Structure

The leadership team includes seasoned executives with experience in pharmaceutical development and commercialization. The organizational structure is typical of a small-cap biopharmaceutical company, with functional departments focusing on R&D, clinical development, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Aphexda (motixafortide): A CXCR4 inhibitor approved by the FDA for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Market share is currently small due to recent launch, but has significant potential. Competitors include stem cell mobilizers, such as plerixafor (Mozobil) from Sanofi.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, specifically in oncology, is characterized by intense competition, high R&D costs, and a complex regulatory landscape. The stem cell mobilization market is driven by the increasing incidence of hematological malignancies and the growing demand for autologous stem cell transplantation.

Positioning

BioLineRx is positioned as a company with an approved product (Aphexda) in the stem cell mobilization market, seeking to capture market share from existing treatments. Its competitive advantage lies in Aphexda's efficacy and safety profile in clinical trials. Its pipeline is limited at this time, but they are working on further developing Aphexda.

Total Addressable Market (TAM)

The global stem cell mobilization market is projected to reach several billion USD. BioLineRx's TAM is a subset of this, specifically the multiple myeloma autologous stem cell transplantation segment. Their success depends on the adoption rate of Aphexda.

Upturn SWOT Analysis

Strengths

  • FDA approved product (Aphexda)
  • Targeted therapy for a specific market
  • Experienced leadership team
  • Strong clinical trial data for Aphexda

Weaknesses

  • Limited product portfolio
  • Reliance on a single product
  • Small market capitalization
  • Need for additional funding

Opportunities

  • Expanding Aphexda's indications to other hematological malignancies
  • Partnerships with larger pharmaceutical companies
  • Geographic expansion
  • Further clinical development of Aphexda in combination therapies

Threats

  • Competition from existing stem cell mobilizers
  • Regulatory hurdles
  • Reimbursement challenges
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • SNY

Competitive Landscape

BioLineRx's advantages include Aphexda's efficacy in clinical trials. Disadvantages include its small size and limited resources compared to larger pharmaceutical companies like Sanofi (SNY).

Growth Trajectory and Initiatives

Historical Growth: Historically, BioLineRx experienced limited growth due to lack of approved products.

Future Projections: Future growth is highly dependent on the successful commercialization of Aphexda. Analyst estimates vary but generally project revenue growth.

Recent Initiatives: Recent initiatives include the launch of Aphexda, expanding its commercial team, and pursuing potential partnerships.

Summary

BioLineRx is a company focused on commercializing Aphexda, approved to treat multiple myeloma. The company will need to successfully launch Aphexda and create new partnerships for continued growth. A small market capitalization and single product focus make it somewhat risky. Future growth will depend on how Aphexda fares in the market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • SEC filings
  • Analyst reports
  • Company Website

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioLineRx Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2011-07-25
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 28
Full time employees 28

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.